ABSTRACT BACKGROUND Concerns exist that women are underrepresented in trials of cardiovascular medications.
C ardiovascular disease (CVD), the leading cause of death among men and women (1), represents a significant women's health concern. Sex and gender differences in CVD pathophysiology, clinical presentation, and outcomes have been described (2) , as have differences in drug safety and efficacy (3) (4) (5) (6) (7) . Sex refers to the biological construct of being male or female according to reproductive organs and chromosomal complement, whereas gender refers to the cultural and social di- Since the mid-1980s, inclusion of women in clinical trials and analyses of potential gender differences in treatment response have been integral to the drug approval process (8) . The U.S. Food and Drug Administration (FDA) continues to advance these efforts (9) by implementing regulations (10) , issuing guidances, assessing demographic inclusion, and conducting of gender analyses (8, 9, 11) . Discussion of demographics of trial participants and subset analyses are built into reviewer templates and addressed in reviewer training (12). The FDA Office of Women's Health coordinates a lecture series on topics pertaining to inclusion of women, subpopulation analysis, and sex and gender differences in disease areas. As a result of these efforts, analyses for potential gender differences in drug trials have increased from 47% (13) (as reported by a survey of sponsors) to >90% (12) (based on FDA's publicly available documents, e.g., reviews and product labeling) since the 1990s.
Over the past several decades, women's participation in clinical trials has improved (14, 15) in some (16) , but not all, CVD areas (17, 18) . Hypothesized obstacles to participation of women include difficulty accessing study sites, familial responsibilities, cultural barriers, socioeconomic barriers, and concerns about risk (19) (20) (21) . The prevalence of CVD is higher in older women (22) , and previous studies have suggested that focus on recruitment of younger patients decreases overall enrollment of women (23) . Inclusion criteria that would tend to select men and exclusion criteria more common in women have also been proposed as contributors (16) . Despite these barriers, examples exist in which women and men showed comparable willingness to enroll in hypothetical (24, 25) and actual (25) (26) (27) CVD trials.
We studied women's participation in CVD trials supporting new drug application (NDA) approvals, as well as gender differences in trial results. For trials with available data, exploratory analyses were conducted to assess the potential impact of study screening criteria on gender differences in enrollment. Table 1 ). Data were collected from trials used to support drug approval. Of the 45 approvals, 9 were excluded for one of the following: pediatric indication, indication not within the 6 cardiovascular therapeutic areas, trial aimed to demonstrate bioequivalence only, or enrollment of <50 subjects (Online Figure 1) . Of the remaining 36 approvals, 1 drug (ticagrelor) was approved for 2 indications (ACS and CAD). Hence, the analyses include 36 approvals (57 trials) for 35 drugs.
PARTICIPATION TO PREVALENCE RATIO.
The participation to prevalence ratio (PPR) is a metric used to describe representation of women in a trial relative to their representation in the disease population (28, 29) . Trial representation was calculated by dividing the number of women in the trial by the total trial enrollment. For each disease area, the percentage of women in the disease population was estimated by dividing the prevalence or incidence of the disease among women by the total prevalence or incidence (Online Table 2 ). If a definitive, gender-stratified estimate was not available, 2 references for the percentage of women in the disease population were u s e dt oc a l c u l a t ear a n g ef o rP P R .T h eP P Rw a s calculated as follows:
A PPR close to 1 indicates that the gender composition of the trial approximates that of the disease population. A PPR <0.8 or >1.2 indicates that women were underrepresented or overrepresented, respectively, relative to the disease population (28, 29 Hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary efficacy endpoint by gender for targeted cardiovascular (CV) trials and categories. The HRs and 95%
confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of gender after adjustment for all other factors.
Apparent homogeneity or heterogeneity among gender should not be overinterpreted. The primary efficacy endpoint and the reference group for each cardiovascular disease (CVD) area/drug are as follows. Acute coronary syndrome (ACS): cangrelor: the composite of all-cause mortality, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis; prasugrel and ticagrelor: the composite of CV death, MI, or stroke (clopidogrel as the reference group for all 3 drugs). Atrial fibrillation (AF): apixaban, dabigatran, edoxaban, rivaroxaban: the composite of stroke or noncentral nervous system systemic embolism (warfarin as the reference group for all 4 drugs); dronedarone: the composite of first CV hospitalization or all-cause mortality (placebo as the reference group). Coronary artery disease (CAD): ticagrelor: the composite of CV death, MI, or stroke; vorapaxar: the composite of CV death, MI, stroke, or urgent coronary revascularization (placebo as the reference group for both drugs). Heart failure (HF): isosorbide/hydralazine: all-cause mortality was presented in this figure instead of the primary efficacy outcome, which was a composite score of clinical outcomes (placebo as the reference group); ivabradine and sacubitril/valsartan: the composite of hospitalization for worsening heart failure or CV death (enalapril as the reference group). Pulmonary arterial hypertension (PAH): macitentan: the composite of death, a significant morbidity event or other worsening PAH (placebo as the reference group). F ¼ female; M ¼ male.
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( Figure 1 ). In Figure 2 , safety results are presented by gender for trials of anticoagulant and antiplatelet drugs with binary protocol-specified safety endpoints (i.e., bleeding yes/no).
For the trials with continuous endpoints, that is, variables that measure the magnitude of an effect and can assume any value within a range (e.g., blood pressure or 6-min walk distance), and/or trials without any pre-specified safety endpoints, we examined FDA reviews and product labeling to identify and describe gender differences in efficacy and safety. The primary efficacy endpoints for the trials with continuous endpoints are described in Online Table 3 .
SCREENING FAILURES BY GENDER. To examine the potential impact of study eligibility criteria on gender differences in study enrollment, 5 NDAs (with available screening data) were examined to determine the numbers of patients not enrolled because of failure to HRs and 95% CIs for bleeding by gender for targeted CV trials and categories. The HR and 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a gender after adjustment for all other factors. Apparent homogeneity or heterogeneity among gender should not be over-interpreted. Definitions for bleeding varied across trials. The reference group for each CVD area is as follows. ACS: clopidogrel as the reference group for all 3 drugs; AF: warfarin as the reference group for all 4 drugs;
and CAD: placebo as the reference group for both drugs. Abbreviations as in Figure 1 . The lowest enrollment of women was in HF (24%) and the highest in PAH (77%) ( Table 1) .
Women were represented at a rate similar to or greater than their share of the disease population in trials in PAH (PPR 1. Table 3 , there were no indications of a gender difference, with 1 exception: for ranolazine, a drug indicated for angina, reductions in angina frequency and nitroglycerin use were less for women, and this is described in product labeling (Online Table 3 ). Table 4 ).
SCREENING FAILURES BY GENDER. Table 2 summarizes the numbers and percentages of women and men who were screened, screened out, and ultimately enrolled (Online Table 5 ). Overall, the percentage of women participating in a screening visit was similar to the percentage of women ultimately enrolled in the trial. Although a higher percentage of women than men were screened out for all 5 trials, differences were modest except for 1 ACS trial where 32% of women were screened out compared with 23% of men.
DISCUSSION
The proportion of women enrolled in cardiovascular trials supporting drug approvals ranged from 22% to 81% (mean per trial 46%) ( Tables 1 and 2 . †Gender-stratified prevalence of atrial fibrillation in a representative population was not available. Two percentages were provided; one based on ageadjusted prevalence using published population-based studies (36%) and the other based on a cohort of atrial fibrillation patients within Kaiser Permanente of Northern California (49%). ‡Trials for heart failure drugs were conducted only among patients with reduced ejection fraction. Gender-stratified prevalence of heart failure with reduced ejection fraction was not available in a representative population. Two percentages were provided; one based on prevalence of all heart failure patients in the United States (53%) and the other based on the Framingham cohort with heart failure with reduced ejection fraction (40%).
CVD ¼ cardiovascular disease.
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In the CAD and ACS/MI trials, 24% and 28% of enrolled patients were women, respectively, with a PPR <0.6 in both areas. In recent surveys of CAD and ACS trials, participation of women ranged between 25% and 33% (16, 17, 33) . Underenrollment of women in these areas has been attributed to underenrollment of elderly patients (35) and the presence of comorbidities such as diabetes (17) . Screening did not exclude nearly enough patients to account for the differences in participation that were observed. Thus, factors before screening, for example, identification of potential trial participants and ability of the candidate to participate, may be more important contributors to low enrollment of women (Online Figure 2) . The data suggest that women are less likely than men to consider participation in trials, and/or they are less likely than men to be considered for screening in trials. We presume that both factors are operational for a variety of reasons, but their elucidation is beyond the scope of this paper. On the basis of our limited data, study inclusion and exclusion criteria appear to exert relatively minor effects on women's participation.
We found few clinically meaningful gender differences in efficacy and safety in the drugs assessed.
Although the 95% confidence intervals include the null value for some subgroups (Figure 1 ) (e.g., tica- Because it is not required for NDA submission, data on screening failures were available from only a small number of NDAs; therefore, our ability to draw conclusions about the effects of screening criteria in clinical trials is limited.
CONCLUSIONS
Based on prevalence-corrected estimates for repres e n t a t i o no fw o m e n ,t r i a l si nh y p e r t e n s i o na n dA F , were within, and trials in PAH were above the pre- 
